Publications by authors named "Hongsong Bai"
Article Synopsis
- Research focused on patients with metastatic clear-cell renal cell carcinoma (mccRCC) receiving immunotherapy and tyrosine kinase inhibitor (TKI) treatments to evaluate the role of serum immunoglobulin G (IgG) as a potential biomarker.
- Findings indicated that while baseline serum IgG levels did not significantly correlate with treatment response, an increase in serum IgG after 3 months of therapy was linked to a worse prognosis, including poorer progression-free survival (PFS) and overall survival (OS).
- The study concluded that elevated serum IgG levels after treatment serve as an independent risk factor for reduced patient outcomes, suggesting that monitoring IgG changes could help in evaluating treatment efficacy in mccRCC patients.
Article Synopsis
- The study examines the role of neutrophil extracellular traps (NETs) as potential biomarkers for predicting the efficacy of systemic therapies in metastatic clear cell renal cell carcinoma (ccRCC).
- NET levels were significantly higher in tumor tissues compared to para-tumor tissues, with correlations found between NET levels and progression-free survival in specific patient groups.
- Elevated NET levels were associated with poorer overall survival across both targeted therapy (TKI) and immune checkpoint inhibitor (IO-TKI) treatments, highlighting their potential as prognostic indicators in ccRCC treatment outcomes.
Article Synopsis
- Primary female urethral carcinomas are rare, usually diagnosed at an advanced stage, and have no standard treatment, making multimodal therapy necessary.
- A case study showed that chemotherapy with albumin-paclitaxel and carboplatin, combined with the PD-1 inhibitor toripalimab, resulted in a complete response in a patient with metastatic squamous cell carcinoma.
- Following 20 months of observation, no recurrence or metastasis was found, suggesting that this combined therapy could be effective for patients with certain genetic markers, though more research is needed to confirm these findings.
Objective: To investigate the efficacy and complications of surgical treatment in patients with renal cell carcinoma aged ≥ 75 years.
Methods: From January 2009 to May 2019, we assessed 166 patients aged 75 years and older, who either had radical nephrectomy (RN) or partial nephrectomy (PN) as treatments for diagnosed renal cell carcinoma. Patients were divided into one group of patients aged 75-79 years and the second group of patients ≥ 80 years.
Background: Whether circulating tumor cells (CTCs) with prostate-specific membrane antigen (PSMA) high expression was related to the metastatic progress in prostate cancer (PCa) remains explored. This study aimed to provide evidence to elucidate this relationship via the telomerase reverse transcriptase (TERT)-based CTC detection method.
Methods: A total of 71 patients were enrolled and divided into the local PCa group (n=44) and metastatic PCa group (n=27).
Background: Prostate-specific antigen (PSA) testing is limited in identifying prostate cancer (PCa) with modestly elevated PSA levels. Therefore, a robust method for the diagnosis of PCa is urgently needed.
Methods: A total of 203 men with a PSA level of ≥4 ng/ml were eligible for enrollment in this study from July 2018 to May 2021, and randomly divided into a training set (n=78) and a validation set (n=125).
Purpose: Reduced quality of life after cystectomy has made bladder preservation a popular research topic for muscle-invasive bladder cancer (MIBC). Previous research has indicated significant tumor downstaging after neoadjuvant chemotherapy (NAC). However, maximal transurethral resection of bladder tumor (TURBT) was performed before NAC to define the pathology, impacting the real evaluation of NAC.
View Article and Find Full Text PDFPurpose: The aim of this study was to evaluate the efficacy and safety of hormonal and synchronous docetaxel plus prednisone (DocP) in metastatic hormone-sensitive prostate cancer (mHSPC).
Methods: One hundred fifty-one cases with high-burden mHSPC diagnosed at 1 single center from January 2014 to August 2018 were analyzed retrospectively. Among them, 85 cases received androgen-deprivation therapy (ADT) within 3 months, along with 6 cycles of docetaxel + prednisone (treatment group), whereas 66 received ADT alone (control group).